To distinguish KRAS-selective effects versus global impacts on Ras-signaling and tumorigenesis by SNARE loss, DLD-1 isogenic colon cancer subclones51, which differ only by whether they express a single WT or oncogenic point mutant KRAS allele, were next used. The gene discussed is KRAS; the disease is malignant colon neoplasm.